Navigation Links
Sweden to Receive Scandinavia's First TomoTherapy System : Lund University Hospital to Offer Swedish Cancer Patients the Most Advanced Image-Guided Radiation Therapy Treatments
Date:7/31/2008

TomoTherapy Incorporated (NASDAQ: TOMO) announced today that it has extended its reach in Europe with the first TomoTherapy HiArt treatment system set to be installed in Scandinavia, at Lund University Hospital in Sweden.

MADISON, Wis. (Business Wire EON) July 31, 2008 -- Jef Van Dam, general manager of TomoTherapyEMEA, said, "TomoTherapy is extremely pleased to partner with Lund University Hospital. This marks our entry into the Swedish market with a prestigious institution that pioneered the use of many technological advances in Scandinavia andEurope. We look forward to delivering the advanced HiArt system to continue that tradition."

Lund University Hospital conducted an extensive investigation of all commercially available intensity-modulated radiation therapy (IMRT) systems, including arc-based options on conventional platforms, before making the decision to purchase the TomoTherapy HiArt system.

Charlott Wictor, strategic purchaser of medical equipment for the Skane region in Sweden, championed TomoTherapy and helped the purchase become reality: "This was a great team effort working with the Lund medical and physics experts to bring this advanced technology to our Swedish patients. TomoTherapy was clearly the best choice from both a high technology and economic standpoint."

Jacob Engellau, M.D., Ph.D., head of radiation oncology at Lund University Hospital, believes TomoTherapy will have a great impact on patient treatments. "As a large center treating 2500 new patients yearly, we are dependent on high up-time and clinical reliability. The established and clinically well-implemented TomoTherapy HiArt was the only system that could meet the demands of our clinic."

Tommy Kns, Ph.D., associate professor and head of radiation physics at Lund University Hospital, was also an important decision maker in the process. "We think TomoTherapy is the most advanced image-guided system for radiotherapy with an integrated functionality for imaging and localisation of the target volume. It also produces the most advantageous dose distributions for IMRT," according to Kns.

Added Engellau, "With the HiArt system, we see obvious clinical advantages for treating complex radiation target volumes, multiple targets and targets requiring a high radiation dose with close proximity to healthy organs. Conventional 3D conformal radiation or IMRT can treat some but not all of these case types. If the cases can be attempted, we believe the results would be less conformal, less accurate and with much longer treatment times than with TomoTherapy."

While TomoTherapy will be used to treat a wide array of cancers, the clinical experts at Lund plan to focus on anal, rectal, cervical, stomach and esophageal cancers. They will also be using the HiArt system for stereotactic radiosurgery treatments and see greater possibilities for clinical trials involving simultaneously integrated boost (SIB) with or without dose escalation.

Lund University Hospital plans to install the TomoTherapy HiArt system later this year.

About TomoTherapy Incorporated

TomoTherapy Incorporated has developed, markets and sells the TomoTherapy HiArt treatment system, an advanced radiation therapy system for the treatment of a wide variety of cancers. The HiArt treatment system combines integrated CT imaging with conformal radiation therapy to deliver sophisticated radiation treatments with speed and precision while reducing radiation exposure to surrounding healthy tissue. The company's stock is traded on the NASDAQ Global Select Market under the symbol TOMO. To learn more about TomoTherapy, please visit TomoTherapy.com.

Forward-Looking Statements

Statements in this release regarding future events, expectations and other similar matters, including but not limited to statements using the terms "look forward to" or "will" constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements contained in this press release are subject to risks and uncertainties that could cause actual results to differ materially from those anticipated, including but not limited to factors such as our ability to integrate acquired assets, ability to protect intellectual property, risks of interruption due to events beyond the company's control, and the other risks listed from time to time in TomoTherapy's filings with the U.S. Securities and Exchange Commission, which by this reference are incorporated herein. These forward-looking statements represent TomoTherapy's judgments as of the date of this press release. TomoTherapy assumes no obligation to update or revise the forward-looking statements in this release because of new information, future events or otherwise.

2008 TomoTherapy Incorporated. All rights reserved.TomoTherapy, the TomoTherapy logo and HiArt are among trademarks, service marks or registered trademarks of TomoTherapy Incorporated.

Read the full story at http://www.prweb.com/releases/tomotherapy/lund_university/prweb1167744.htm


'/>"/>
Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Nephros Exhibits at the XLV ERA-EDTA Congress in Stockholm, Sweden, May 10-13, 2008
2. The Feinstein to collaborate with Swedens Karolinska Institute
3. Medco Partners to Develop Patient-Safety System for Prescription Drugs in Sweden
4. University of South Florida receives new multimillion award to assess juvenile diabetes treatments
5. Lupin Receives USFDA Approval for Divalproex Sodium Delayed-Release Tablets
6. Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA Approval for Simvastatin Tablets
7. Go Healthy Receives Letter of Recognition From the Texas Chiropractic Association
8. Eagle Ventures Subsidiary Hydrate2O Receives 2008 Top Gear of the Year Award From ShapeYou.com
9. Escalon(R) Receives FDA 510(k) Clearance to Market the LIASYS(TM) Clinical Chemistry and Immunoturbidimetric Analyzer
10. French Agency Receives 10 Million Dollar Grant From the Bill & Melinda Gates Foundation to Support the Establishment of National Vaccine Advisory Committees in Africa and Asia
11. Pandemic research receives $1.6M funding boost
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
 Sweden to Receive Scandinavia's First TomoTherapy System :  Lund University Hospital to Offer Swedish Cancer Patients the Most Advanced Image-Guided Radiation Therapy Treatments 
(Date:2/12/2016)... Appleton, Wis. (PRWEB) , ... February 12, 2016 ... ... its second Lean Leadership Series at Zuckerberg San Francisco General Hospital on April ... to practice new behaviors and create new habits. The workshops cover a broad ...
(Date:2/12/2016)... , ... February 12, 2016 , ... Fisher House Foundation ... Mayor John J. Lee, Nevada Military Support Alliance president Scott Bensing, and Peggy Kearns ... the VA Southern Nevada Healthcare System. This will be the first Fisher House ...
(Date:2/12/2016)... ... 12, 2016 , ... Vail knee specialist Robert LaPrade, MD, PhD ... . The list consists of physicians establishing, leading and partnering with ambulatory surgery centers ... An Ambulatory Surgery Center, also known as an ASC, is a modern health care ...
(Date:2/12/2016)... ... 12, 2016 , ... Donor Network West, the organ procurement organization that heals ... with San Ramon Regional Medical Center. Under the collaboration, the first of its kind, ... accommodate a more certain time frame for donor families for the recovery of organs. ...
(Date:2/12/2016)... ... February 12, 2016 , ... ... surrounding communities by continuing it’s commitment to act as Agents of Change in ... works closely with area homeless families to fulfill immediate needs and help them ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... --> ... Global Clinical Trials Review, H2, 2015 provides an ... trials landscape along with top level data related ... & E7), Trial Status, Trial Phase, Sponsor Type ... involved and enlists all trials (Trial title, Phase, ...
(Date:2/11/2016)... 11, 2016 Stem cells are primitive cells ... self-renewal and the capacity to differentiate into mature cell ... as the first mouse embryonic stem cells were derived ... 1995 that the first culturing of embryonic stem cells ... not produced until 2006 As a result of these ...
(Date:2/11/2016)... -- Kindred Biosciences, Inc. (NASDAQ: KIN ), a biopharmaceutical ... pets, today announced the submission to FDA of the ... (NADA) for Zimeta™ (dipyrone injection, KIND-012).  Positive topline results ... the control of pyrexia (fever) in horses were recently ... --> The Chemistry, Manufacturing, and Controls technical ...
Breaking Medicine Technology: